Biotricity Stock (NASDAQ:BTCY), Trade Ideas

Biotricity

Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed, which is a virtual clinic platform that enables clinicians to provide outstanding patient care remotely; Bioheart, which is a personal heart monitor; and Biocare health.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AEYE

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BHVN

BTCY

CENX

CMAX

Envoy Medical, Inc. - Class A Common Stock

COCH

DXYZ

EGIO

EXTR

HUBC

IMCC

INFA

KAVL

KUKE

LGVN

LOCL

MNDR

MRNS

NMRA

Nuveen California Dividend Advantage Municipal Fund 2

NXPL

ONVO

PROK

PSNY

QTTB

RARE

RENT

SNGX

SNPO

SPCB

SPWR

SRFM

SWVL

TCON

VERU

VIAO

WIRE

Shares of  Ultragenyx Pharmaceutical Inc.  (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

AGRI

ANTE

BFRI

BTTX

CISO

CURO

EVLV

GXAI

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INMD

IOVA

LICN

LUNR

LXRX

MEDS

MNPR

OCGN

OPEN

QBTS

QRTEA

RAPT

SIEN

SISI

SMCI

SMMT

SPRC

SSRM

TANH

TIRX

TNYA

TVGN

VZIO

Shares of  Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.

Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

ACMR

AIRE

AMZN

APLM

APPF

ARCB

BHAT

BHIL

BKYI

BREA

BWMX

CUBI

DECK

DXCM

ENPH

EXPO

GNLX

GTLS

IBRX

IMTE

INTC

KNSL

LRHC

MDNA

NKGN

NRDS

NVVE

RNAZ

RVSN

SAIA

SECO

SYTA

TMPO

VVOS

Gainers


	Apollomics, Inc.  (NASDAQ: APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion.


Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Biotricity Inc

<a href="https://www.statnews.com/2024/05/07/duchenne-muscular-dystrophy-pfizer-gene-therapy-boy-dies/" title="https://www.statnews.com/2024/05/07/duchenne-muscular-dystrophy-pfizer-gene-therapy-boy-dies/">https://www.statnews.com/2024/05/07/duchenne-muscular-dystrophy-pfizer-gene-therapy-boy-dies/</a>

Watching Pfizer Shares; Traders Circulating STAT News Report 'Young boy dies in trial for Pfizer Duchenne gene therapy'

Whales with a lot of money to spend have taken a noticeably bearish stance on Unity Software.
Looking at options history for Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $280,713 and 3, calls, for a total amount of $157,010.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $22.0 to $35.0 for Unity Software over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Unity Software's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Unity Software's whale activity within a strike price range from $22.0 to $35.0 in the last 30 days. 
<h3>Unity Software 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715110249_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$1.93</td>
<td>$1.88</td>
<td>$1.89</td>
<td>$27.00</td>
<td>$94.5K</td>
<td style="text-align: right;">896</td>
<td style="text-align: right;">533</td>
</tr>
<tr>
<td>U</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.69</td>
<td>$2.67</td>
<td>$2.69</td>
<td>$22.00</td>
<td>$83.9K</td>
<td style="text-align: right;">130</td>
<td style="text-align: right;">651</td>
</tr>
<tr>
<td>U</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$13.85</td>
<td>$11.95</td>
<td>$12.85</td>
<td>$35.00</td>
<td>$75.8K</td>
<td style="text-align: right;">404</td>
<td style="text-align: right;">39</td>
</tr>
<tr>
<td>U</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$2.75</td>
<td>$2.71</td>
<td>$2.75</td>
<td>$26.00</td>
<td>$55.0K</td>
<td style="text-align: right;">976</td>
<td style="text-align: right;">609</td>
</tr>
<tr>
<td>U</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.7</td>
<td>$2.66</td>
<td>$2.66</td>
<td>$22.00</td>
<td>$39.9K</td>
<td style="text-align: right;">130</td>
<td style="text-align: right;">801</td>
</tr>
</tbody>
</table>

<h3>About Unity Software</h3>
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Following our analysis of the options activities associated with Unity Software, we pivot to a closer look at the company's own performance.
<h3>Unity Software's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 2,370,831, the U's price is down by -0.47%, now at $25.37. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 2 days.</li>
</ul>
<h3>What Analysts Are Saying About Unity Software</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $33.5.
<ul>
<li>An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $33. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Unity Software, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Behind the Scenes of Unity Software's Latest Options Trends

Investors with a lot of money to spend have taken a bullish stance on Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with EXPE, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Expedia Group.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 37%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $597,000, and 7, calls, for a total amount of $298,477.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $95.0 and $145.0 for Expedia Group, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Expedia Group stands at 695.88, with a total volume reaching 1,106.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Expedia Group, situated within the strike price corridor from $95.0 to $145.0, throughout the last 30 days.
<h3>Expedia Group Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715110243_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXPE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$10.1</td>
<td>$9.8</td>
<td>$9.95</td>
<td>$110.00</td>
<td>$597.0K</td>
<td>2.7K</td>
<td style="text-align: right;">602</td>
</tr>
<tr>
<td>EXPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$4.15</td>
<td>$4.05</td>
<td>$4.15</td>
<td>$115.00</td>
<td>$69.3K</td>
<td>997</td>
<td style="text-align: right;">121</td>
</tr>
<tr>
<td>EXPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$5.95</td>
<td>$5.95</td>
<td>$5.95</td>
<td>$130.00</td>
<td>$59.5K</td>
<td>37</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>EXPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$5.95</td>
<td>$5.8</td>
<td>$5.85</td>
<td>$125.00</td>
<td>$38.6K</td>
<td>265</td>
<td style="text-align: right;">91</td>
</tr>
<tr>
<td>EXPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$7.45</td>
<td>$7.3</td>
<td>$7.39</td>
<td>$120.00</td>
<td>$37.6K</td>
<td>214</td>
<td style="text-align: right;">64</td>
</tr>
</tbody>
</table>

<h3>About Expedia Group</h3>
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2023 sales), air tickets (3%), rental cars, cruises, in-destination, and other (11%), and advertising revenue (6%). Expedia operates a number of branded travel booking sites, but its three core onlint travel agency brands are Expedia, Hotels.com, and Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
<h3>Current Position of Expedia Group</h3>
<ul>
<li>Trading volume stands at 2,923,830, with EXPE's price down by -2.79%, positioned at $112.78.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 86 days.</li>
</ul>
<h3>What Analysts Are Saying About Expedia Group</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $149.4.
<ul>
<li>An analyst from Piper Sandler downgraded its action to Neutral with a price target of $145. </li>
<li>Maintaining their stance, an analyst from HSBC continues to hold a Hold rating for Expedia Group, targeting a price of $132. </li>
<li>An analyst from RBC Capital has decided to maintain their Sector Perform rating on Expedia Group, which currently sits at a price target of $140. </li>
<li>Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Expedia Group with a target price of $175. </li>
<li>Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Expedia Group with a target price of $155. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Expedia Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

EXPE

What the Options Market Tells Us About Expedia Group

Deep-pocketed investors have adopted a bearish approach towards CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 14 extraordinary options activities for CVS Health. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 35% leaning bullish and 50% bearish. Among these notable options, 6 are puts, totaling $359,888, and 8 are calls, amounting to $809,996.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $92.5 for CVS Health during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of CVS Health stands at 866.15, with a total volume reaching 2,709.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in CVS Health, situated within the strike price corridor from $50.0 to $92.5, throughout the last 30 days.
<h3>CVS Health 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715110238_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.3</td>
<td>$4.85</td>
<td>$5.0</td>
<td>$65.00</td>
<td>$500.0K</td>
<td style="text-align: right;">234</td>
<td>1.0K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$10.1</td>
<td>$10.05</td>
<td>$10.1</td>
<td>$65.00</td>
<td>$95.9K</td>
<td style="text-align: right;">259</td>
<td>74</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$7.4</td>
<td>$7.3</td>
<td>$7.4</td>
<td>$62.50</td>
<td>$85.8K</td>
<td style="text-align: right;">692</td>
<td>140</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$8.4</td>
<td>$7.7</td>
<td>$7.75</td>
<td>$55.00</td>
<td>$77.5K</td>
<td style="text-align: right;">765</td>
<td>20</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$10.15</td>
<td>$10.0</td>
<td>$10.1</td>
<td>$65.00</td>
<td>$73.7K</td>
<td style="text-align: right;">259</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the U.S. CVS is also the largest pharmacy benefit manager (acquired through Caremark), processing over 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
After a thorough review of the options trading surrounding CVS Health, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>CVS Health's Current Market Status</h3>
<ul>
<li>With a volume of 11,616,819, the price of CVS is down -0.36% at $55.77. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 85 days.</li>
</ul>
<h3>Expert Opinions on CVS Health</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $72.2.
<ul>
<li>An analyst from B of A Securities persists with their Buy rating on CVS Health, maintaining a target price of $77. </li>
<li>Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on CVS Health with a target price of $76. </li>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $87. </li>
<li>Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $58.</li>
<li>Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on CVS Health with a target price of $63. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for CVS Health with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

CVS Health Options Trading: A Deep Dive into Market Sentiment

In a move that could lower its dependence on external chip manufacturers like NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly developing its own chips.
According to a <a href="https://www.wsj.com/tech/ai/apple-is-developing-ai-chips-for-data-centers-seeking-edge-in-arms-race-0bedd2b2">report</a> from the Wall Street Journal, these chips are designed to run artificial intelligence (AI) software within data centers.
What Happened: Apple has been working on a project, termed ACDC (Apple Chips in Data Center), for several years, WSJ reports. The tech giant has been partnering with Taiwan Semiconductor Manufacturing Co. for the chip&#8217;s design and production, but the success of these efforts is still uncertain.
The Wall Street Journal suggests that Apple&#8217;s server chip will likely concentrate on AI inference rather than training AI models, an area that experts believe NVIDIA will continue to dominate. AI inference is the process whereas trained machine learning models draw conclusions from new data.
See Also:<a href="https://www.benzinga.com/news/24/05/38635052/house-minority-leader-hakeem-jeffries-warns-of-dire-consequences-for-womens-reproductive-rights-if-t?itm_source=parsely-api"> House Minority Leader Hakeem Jeffries Warns Of Dire Consequences For Women&#8217;s Reproductive Rights If Trump</a>
Apple&#8217;s initiative is similar to other tech giants like Google&#8217;s parent company Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), which is also developing its own AI inference server chips to reduce reliance on chip designers. However, experts note that Apple is still trailing rivals such as Microsoft in the AI technology race.
Apple CEO Tim Cook stated in February that the company was &#8220;investing significantly&#8221; in AI technology and would make an AI-related announcement later this year. The announcement is anticipated at the Worldwide Developers Conference in June.
Why It Matters: Apple&#8217;s move to develop in-house AI chips is part of a broader trend among tech companies to reduce their dependence on external chip manufacturers. According to a<a href="https://www.theverge.com/2024/5/6/24150742/apples-project-acdc-is-building-ai-chips-for-data-centers"> report </a>by The Verge, companies like Google, Meta, Microsoft, and OpenAI are also working on custom server hardware to power AI models. 
This shift towards in-house development could potentially disrupt the traditional chip manufacturing industry, particularly affecting companies like NVIDIA that have a significant market share. But, because Apple's new chips are likely to focus on areas outside of NVIDIA's expertise, it's probable that there will be space for both of the tech giants in the AI race.
Read Next:<a href="https://www.benzinga.com/news/24/05/38673436/apple-launches-ipad-pro-with-m4-chip-oled-display-at-999-ipad-air-6-now-comes-in-two-sizes-for-the-f"> Apple Launches iPad Pro With M4 Chip, OLED Display At $999: iPad Air Now Comes In Two Sizes For The First Time</a>
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Shutterstock

General

AAPL

GOOG

NVDA

Apple's Secret Project And Bold Move Towards In-House AI Chips: Could This Be A Threat To NVIDIA?

Activist groups in Germany are targeting electric vehicle (EV) manufacturer Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) as it works to <a href="https://www.benzinga.com/news/24/03/38001324/german-chancellor-olaf-scholz-calls-arson-attack-on-teslas-giga-berlin-a-terrorist-act-wants-ev-gian">expand its Giga Berlin factory.</a>
What Happened: The Austin, Texas-based car company faces upcoming<a href="https://www.benzinga.com/news/24/03/37573105/elon-musk-declares-tesla-is-hardcore-ahead-of-giga-berlins-production-restart"> protests at Giga Berlin </a>and is taking preventative measures, including a four-day closure, according to German business newspaper <a href="https://www.handelsblatt.com/unternehmen/industrie/elektromobilitaet-tesla-legt-produktion-in-gruenheide-fuer-vier-tage-still/100037131.html">Handelsblatt</a>. 
The shutdown comes as a result of announced multi-day protests against Tesla.
As a result, Tesla employees are being told to work from home. An email sent to employees on Monday shared the company's decision, according to the report.
Employees in vehicle production will see Friday a bridge day. Production is ending with the late shift on Wednesday and will begin again with the night shift on Sunday.
"No access to the site or the factory is possible without the explicit instructions and approval of your manager," an email obtained by Handelsblatt reads. &nbsp;
Tesla also said there would be no buses or trains running to the gigafactory in Germany from Thursday through Sunday.
The company said the move was done as "the corresponding recommendation from the responsible authorities."
Related Link: <a href="https://www.benzinga.com/news/earnings/24/04/38390883/tesla-q1-earnings-highlights-ev-giant-misses-wall-street-estimates-makes-cost-cuts-invests-in-ai-sp">Tesla Q1 Earnings Highlights: EV Giant Misses Wall Street Estimates, Makes Cost Cuts, Invests In AI, Speeds Launch Of New Models</a>
Why It's Important: Tesla influencers dispute the accuracy of the four-day closure report.
Tesla delivery vehicle tracker Troy Teslike <a href="https://twitter.com/TroyTeslike/status/1787902806420021732">said </a>that Thursday is a public holiday in Germany (Ascension Day) and the factory is typically open Monday through Friday.
"This production pause is only for 1 day (Friday)," Teslike said. "It won't affect deliveries because Model Y inventory in Europe is at an all-time high due to limited demand."
Tesla influencer Sawyer Merritt <a href="https://twitter.com/SawyerMerritt/status/1787898939489804371">called </a>an article from Reuters citing the four-day work pause as misleading.
"This headline is a little misleading. Giga Berlin usually produces cars Monday-Friday. This Thursday is a Holiday, so really it's just a one-day shutdown," Merritt tweeted.
News of the work pause and the work-from-home orders come as Tesla CEO Elon Musk has famously been an outspoken critic of employees working from home.
The CEO has <a href="https://www.benzinga.com/news/23/05/32437964/elon-musk-paints-remote-work-as-morally-wrong-says-laptop-classes-are-living-in-la-la-land">called work from home</a> "morally wrong" and has made it mandatory for Tesla and social media platform X that employees work in office except in limited scenarios.
While the work stoppage could end up being only one day due to the holiday, it bears watching as an arson attack led to the plant temporarily shutting down in Germany.
Protestors are expected to convene in front of the factory on Friday. The goal is to raise awareness for the clearing of a forest area by Tesla if it expands the factory. The expansion has faced pushback and the protest could bring more attention to the concerns raised against Tesla's move to grow.
Read Next: <a href="https://www.benzinga.com/news/24/05/38648277/tesla-lays-off-more-employees-over-weekend-report">Tesla Lays Off More Employees Over Weekend: Report</a>

TSLA

Tesla Will Temporarily Stop Production At German Gigafactory: Here's Why

<a href="https://www.ft.com/content/cf965960-b083-49ee-bae1-6ce95fe872a3" title="https://www.ft.com/content/cf965960-b083-49ee-bae1-6ce95fe872a3">https://www.ft.com/content/cf965960-b083-49ee-bae1-6ce95fe872a3</a>

Politics

ASML

AVGO

QCOM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

'US to revoke licences for supply of chips to China's Huawei' -Financial Times

Electric vehicle company Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) reported first-quarter financial results Monday that saw revenue beat and earnings per share miss <a href="https://www.benzinga.com/news/earnings/24/05/38653616/lucid-q1-earnings-highlights-revenue-beat-eps-miss-production-update-and-more">Street consensus estimates.</a>
Analysts size up the results and what's next for the company.
The Lucid Analysts: 
<ul>
<li>Stifel analyst Stephen Gengaro has a Hold rating and $4 price target on Lucid.</li>
<li>Needham analyst Chris Pierce has a Hold rating and no price target on Lucid.</li>
</ul>
Related Link: <a href="https://www.benzinga.com/news/earnings/24/05/38670685/whats-going-on-with-lucid-stock-tuesday">What&#8217;s Going On With Lucid Stock Tuesday?</a>
Stifel on Lucid: The first quarter report had mixed results and no real surprises for 2024, Gengaro said.
The analyst said guidance for producing 9,000 vehicles in 2024 was reiterated by the company.
"While first-quarter production numbers came in lighter-than-expected, we believe the company's 9,000 vehicle production target for the year is reasonable," Gengaro said.
The analyst highlighted gross losses improving in the quarter.
"Lucid remains laser-focused on aligning production with demand while controlling costs."
Gengaro said the company's financial position should get it through "at least the launch" of the Lucid Gravity SUV. Additional capital could be needed after this key event with high cash burn, the analyst said.
The analyst said that while production is improving for Lucid, the company could still be in the "prove-it-to-me stage."
Needham on Lucid: Consumers and OEM partners are "still in park" as Lucid looks to grow its production, Pierce said.
"We continue to be believers in LCID's best in class technology driving industry leading efficiency, but we also continue to see low absolute delivery numbers, limiting fixed cost absorption driving financial statement losses and driving further capital needs," Pierce said.
The analyst said Lucid is confident that the Lucid Gravity SUV will be well received by consumers.
Pierce cautions that for bears, Lucid could be "a catalyst light story."
"We continue to think investors will take a conservative posture when considering the low penetration of LCID's existing lineup."
The analyst said investors could be underestimating the technology leadership Lucid has, and the deep pockets of the Saudi Arabian Public Investment Fund allow for patience.
LCID Price Action: Lucid shares are down 14% to $2.65 versus a 52-week trading range of $2.29 to $8.37. Lucid stock is down 66% over the last year.
Read Next: <a href="https://www.benzinga.com/news/24/05/38663810/lucid-ceo-throws-down-the-gauntlet-with-48k-ev-plan-to-take-on-teslas-dominance-wait-until-our-midsi">Lucid CEO Throws Down The Gauntlet With $48K EV Plan To Take On Tesla&#8217;s Dominance: &#8216;Wait Until Our Midsize Comes Out In Late 2026&#8217;</a>
Photo: Shutterstock<a href="https://www.benzinga.com/news/24/05/38663810/lucid-ceo-throws-down-the-gauntlet-with-48k-ev-plan-to-take-on-teslas-dominance-wait-until-our-midsi"> </a>

Analyst Color

Price Target

Reiteration

Analyst Ratings

Tech

LCID

Electric Up-And Comer Lucid's Stock 'Still In Park': Analysts Expect Investors To Keep 'Conservative Posture' On Tesla Rival

<a href="https://twitter.com/CGasparino/status/1787921614312718571" title="https://twitter.com/CGasparino/status/1787921614312718571">https://twitter.com/CGasparino/status/1787921614312718571</a>

Watching Boeing Shares; Charles Gasparino Tweets Co Is Seeking Investment From Warren Buffett

Over the past 24 hours, Optimism's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">OP</a>) price has fallen 3.73% to $2.7. This is opposite to its positive trend over the past week where it has experienced a 15.0% gain, moving from $2.33 to its current price. 
The chart below compares the price movement and volatility for Optimism over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715108623_0.png" alt="price_chart" />
The trading volume for the coin has fallen 23.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has decreased 0.21%. This brings the circulating supply to 1.05 billion, which makes up an estimated 24.34% of its max supply of 4.29 billion. According to our data, the current market cap ranking for OP is #46 at $2.82 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715108623_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Cryptocurrency Optimism Down More Than 3% Within 24 hours

Over the past 24 hours, Filecoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/fil/usd">FIL</a>) price has fallen 3.72% to $5.91. This is opposite to its positive trend over the past week where it has experienced a 8.0% gain, moving from $5.55 to its current price. 
The chart below compares the price movement and volatility for Filecoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715108554_0.png" alt="price_chart" />
The trading volume for the coin has decreased 27.0% over the past week, while the overall circulating supply of the coin has increased 1.07% to over 548.38 million. This puts its current circulating supply at an estimated 27.97% of its max supply, which is 1.96 billion. The current market cap ranking for FIL is #37 at $3.24 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715108554_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$FIL

Cryptocurrency Filecoin Down More Than 3% Within 24 hours

dogwifhat's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) price has decreased 3.31% over the past 24 hours to $3.26. This is contrary to the coins performance over the past week where it has experienced an up-trend of 40.0%, moving from $2.38 to its current price.
The chart below compares the price movement and volatility for dogwifhat over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715108545_0.png" alt="price_chart" />
The trading volume for the coin has increased 54.0% over the past week while the overall circulating supply of the coin has increased 1.3% to over 998.93 million which makes up an estimated 100.0% of its max supply, which is 998.93 million. The current market cap ranking for WIF is #36 at $3.26 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715108545_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$WIF

Cryptocurrency dogwifhat Down More Than 3% Within 24 hours

Pepe's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) price has decreased 4.34% over the past 24 hours to $0.0000082. This is contrary to the coins performance over the past week where it has experienced an up-trend of 27.0%, moving from $0.0000065 to its current price.
The chart below compares the price movement and volatility for Pepe over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715108475_0.png" alt="price_chart" />
The trading volume for the coin has decreased 20.0% over the past week, while the overall circulating supply of the coin has increased 0.35% to over 420.69 trillion. This puts its current circulating supply at an estimated 100.0% of its max supply, which is 420.69 trillion. The current market cap ranking for PEPE is #34 at $3.43 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715108475_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$PEPE

Cryptocurrency Pepe Falls More Than 4% In 24 hours

Ratings for TPG RE Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRTX#NYSE">TRTX</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.7, a high estimate of $9.00, and a low estimate of $6.50. Observing a 15.44% increase, the current average has risen from the previous average price target of $6.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1715108476_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of TPG RE Finance Trust among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Stephen Laws</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$8.50</td>
<td>-</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$7.50</td>
<td>$7.00</td>
</tr>
<tr>
<td>Eric Dray</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Underperform</td>
<td>$6.50</td>
<td>-</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to TPG RE Finance Trust. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of TPG RE Finance Trust compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of TPG RE Finance Trust's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of TPG RE Finance Trust's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TRTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on TPG RE Finance Trust analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About TPG RE Finance Trust</h2>
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.
<h3>Financial Milestones: TPG RE Finance Trust's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining TPG RE Finance Trust's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 51.45% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: TPG RE Finance Trust's net margin excels beyond industry benchmarks, reaching 33.95%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): TPG RE Finance Trust's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.16%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.32%, the company showcases effective utilization of assets.
Debt Management: TPG RE Finance Trust's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 2.37.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TRTX

Evaluating TPG RE Finance Trust: Insights From 5 Financial Analysts

Analysts' ratings for Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Integra Lifesciences, presenting an average target of $33.5, a high estimate of $49.00, and a low estimate of $24.00. Observing a downward trend, the current average is 23.2% lower than the prior average price target of $43.62. 
<img src="https://www.benzinga.com/files/images/story/2024/1715108451_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Integra Lifesciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$24.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$40.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$25.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$26.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$49.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Integra Lifesciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Integra Lifesciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Integra Lifesciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Integra Lifesciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/IART/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Integra Lifesciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Integra Lifesciences Better</h2>
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
<h3>Financial Milestones: Integra Lifesciences's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Integra Lifesciences's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -0.25% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.0%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.25%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Integra Lifesciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.53%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.06.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IART

A Glimpse Into The Expert Outlook On Integra Lifesciences Through 8 Analysts

4 analysts have shared their evaluations of Frontier Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FYBR#NASDAQ">FYBR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Frontier Communications, presenting an average target of $32.75, a high estimate of $39.00, and a low estimate of $30.00. Experiencing a 0.76% decline, the current average is now lower than the previous average price target of $33.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1715108444_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Frontier Communications's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Gregory Williams</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Shipra Pandey</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Frontier Communications. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Frontier Communications compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Frontier Communications's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Frontier Communications's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FYBR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Frontier Communications analyst ratings.</a>
<h2>Discovering Frontier Communications: A Closer Look</h2>
Frontier Communications Parent Inc offers a variety of services to residential and business customers over its fiber-optic and copper networks, including video, high-speed internet, advanced voice, and Frontier Secure digital protection solutions. It offers communications solutions to small, medium, and enterprise businesses.
<h3>Frontier Communications's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Frontier Communications's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 1.97%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Frontier Communications's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 0.07%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Frontier Communications's ROE excels beyond industry benchmarks, reaching 0.02%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.0%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 2.14.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FYBR

Demystifying Frontier Communications: Insights From 4 Analyst Reviews

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.38, along with a high estimate of $9.00 and a low estimate of $3.50. This upward trend is evident, with the current average reflecting a 84.5% increase from the previous average price target of $4.00.
<img src="https://www.benzinga.com/files/images/story/2024/1715108434_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Ovid Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$3.50</td>
<td>$4.00</td>
</tr>
<tr>
<td>Kalpit Patel</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$9.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$9.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Announces</td>
<td>Outperform</td>
<td>$8.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ovid Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ovid Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Ovid Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ovid Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OVID/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ovid Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Ovid Therapeutics: A Closer Look</h2>
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
<h3>Ovid Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Ovid Therapeutics showcased positive performance, achieving a revenue growth rate of 205.88% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -10823.47%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -16.21%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -11.39%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Ovid Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OVID

Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics

In the last three months, 8 analysts have published ratings on Spirit Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Spirit Airlines, presenting an average target of $3.67, a high estimate of $4.00, and a low estimate of $3.00. Highlighting a 41.56% decrease, the current average has fallen from the previous average price target of $6.28. 
<img src="https://www.benzinga.com/files/images/story/2024/1715108425_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Spirit Airlines by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helane Becker</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Michael Linenberg</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Stephen Trent</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$3.85</td>
<td>$4.00</td>
</tr>
<tr>
<td>Helane Becker</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Negative</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Duane Pfenningwerth</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$3.50</td>
<td>$18.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Announces</td>
<td>Underweight</td>
<td>$4.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Trent</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$4.00</td>
<td>$3.95</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Spirit Airlines. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Spirit Airlines compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Spirit Airlines's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Spirit Airlines's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SAVE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Spirit Airlines analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Spirit Airlines</h2>
Spirit Airlines Inc serves the United States, Latin America, and Caribbean as an airline operator. It primarily offers customers unbundled base fares to strip out any unneeded travel amenities. If needed, a customer can elect for additional options at an extra charge. Flight crews are entirely interchangeable across all aircraft, and maintenance and other support services are simplified due to not having an overly complex fleet. The company has one operating segment, air transportation, owing to its system wide route structure. It may decide to expand its network if a market is underserved or overpriced. The majority of revenue is derived from the United States.
<h3>Financial Milestones: Spirit Airlines's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Spirit Airlines's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -5.0%. This indicates a decrease in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Spirit Airlines's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -13.89%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -14.99%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Spirit Airlines's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.96%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Spirit Airlines's debt-to-equity ratio surpasses industry norms, standing at 6.11. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SAVE

In-Depth Examination Of 8 Analyst Recommendations For Spirit Airlines

Chegg Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) faces a substantial challenge from the emergence of AI tools such as ChatGPT, which have exerted significant pressure on the company&#8217;s market performance.
The latest earnings report reflects a concerning trend for Chegg, with Quarter 1 revenue down 7% year-over-year and Subscription Service Revenue down 9% year-over-year. Projections for the current quarter indicate further declines in total net revenue, gross margins and profits.
Despite incorporating AI features and enhancements into their products, Chegg struggles to compete with OpenAI's ChatGPT and other freely available AI tools.
Don't Miss:
<ul>
<li>This Uber-for-moving startup is quietly taking the world by storm,<a href="https://www.benzinga.com/money/muvr"> here&#8217;s how anyone can invest for a limited time</a>.</li>
<li>Invest in time-tested solution that aims to solve this $600 billion women&#8217;s health problem<a href="https://www.benzinga.com/money/rootless"> at 80 cents per share</a>.</li>
</ul>
"We've embraced AI and have completely rebuilt our user experience and services, rolling out a multi-year product-led growth plan to emerge from the post-COVID period and return to revenue and profit growth. The transition will take time, but we are already seeing encouraging signs of how our new AI-enabled platform will serve more students, in more ways, than ever before,"&nbsp; said Dan Rosensweig, CEO &amp; President of Chegg in the earnings call.&nbsp;
The Chegg Study Pack, priced at $14.95 per month, offers students access to homework solutions, expert Q&amp;As, plagiarism scanners and math solutions. However, this price point becomes less appealing as students increasingly turn to free or low-cost alternatives for academic assistance.
Trending: Invest like a millionaire. Exclusive opportunity to<a href="https://www.benzinga.com/money/epic-games"> invest in Epic Games $17 billion gaming empire.</a>
Chegg has also announced that the current CEO, Dan Rosensweig, will be replaced by Nathan Schultz. 
&#8220;Nathan has been core to Chegg's success from our earliest days as a textbook rental company to leveraging AI today to create a truly personalized learning assistant,&#8221; said Rosensweig. &#8220;As we are seeing encouraging signs of how our new AI-enabled platform will serve more students, in more ways, it's the right time for Nathan to step in and lead, and I could not be more excited about Chegg's future."&nbsp;
Following this leadership transition, Chegg&#8217;s stock dropped over 27% on Tuesday, currently resting at $5.21. Year-to-date, the stock price has plummeted by over 50%.
Other EdTech platforms, such as Coursera, are also feeling the impact of AI disruption. Despite a 14.5% year-on-year increase in revenue, Coursera missed revenue estimates by 7.8%, leading to an 18% drop in its stock price on Monday. Coursera&#8217;s stock price has fallen over 46% since the beginning of the year.
Keep Reading:
<ul>
<li>Here is where<a href="https://www.benzinga.com/money/ourcrowd"> your most successful angel investment</a> may be hidden.</li>
<li>A groundbreaking energy company plugs into the<a href="https://www.benzinga.com/money/dunamis-2"> $400 billion EV industry and is seeking investors</a>.</li>
</ul>

CHGG

Chegg's Stock Price Drops 27% As ChatGPT And Free AI Tools Send Stock Plummeting

7 analysts have expressed a variety of opinions on OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for OrthoPediatrics, presenting an average target of $40.29, a high estimate of $50.00, and a low estimate of $32.00. Witnessing a positive shift, the current average has risen by 20.88% from the previous average price target of $33.33.
<img src="https://www.benzinga.com/files/images/story/2024/1715108412_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive OrthoPediatrics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$32.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to OrthoPediatrics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OrthoPediatrics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of OrthoPediatrics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of OrthoPediatrics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/KIDS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OrthoPediatrics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering OrthoPediatrics: A Closer Look</h2>
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
<h3>OrthoPediatrics's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining OrthoPediatrics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 21.36% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: OrthoPediatrics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -17.79%, the company may face hurdles in effective cost management.
Return on Equity (ROE): OrthoPediatrics's ROE stands out, surpassing industry averages. With an impressive ROE of -1.78%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.54%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.03, OrthoPediatrics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KIDS

Expert Ratings For OrthoPediatrics

Biotricity posts $14M revenue run rate in August

Sanofi, Dexcom among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.



Moving stocks are earnings reports, clinical trial results, stock offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Senti Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) stock is rocketing more than 141% after announcing a <a href="https://www.nasdaq.com/press-release/senti-bio-announces-new-strategic-collaboration-with-celest-therapeutics-for-clinical">new strategic collaboration in China</a>.</li>



<li>Tharimmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) shares are soaring over 66% after announcing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317846100&amp;type=PDF&amp;symbol=THAR&amp;cdn=0a9c678d9ed42b75b2274fe6f834ea77&amp;companyName=Tharimmune+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2023-11-06">proposed stock offering</a>.</li>



<li>TransMedics (NASDAQ:<a href="https://investorplace.com/stock-quotes/tmdx-stock-quote/">TMDX</a>) stock is surging more than 41% with the release of its <a href="https://www.nasdaq.com/press-release/transmedics-reports-third-quarter-2023-financial-results-2023-11-06">Q3 earnings report</a>.</li>



<li>Unisys (NYSE:<a href="https://investorplace.com/stock-quotes/uis-stock-quote/">UIS</a>) shares are gaining close to 25% after releasing its <a href="https://finance.yahoo.com/news/unisys-q3-earnings-snapshot-220633798.html">Q3 earnings report</a>.</li>



<li>Biotricity (NASDAQ:<a href="https://investorplace.com/stock-quotes/btcy-stock-quote/">BTCY</a>) stock is increasing over 24% after issuing an unsecured convertible preferred note for $1 million.</li>



<li>Clean Earth Acquisitions (NASDAQ:<a href="https://investorplace.com/stock-quotes/clinr-stock-quote/">CLINR</a>) shares are rising more than 19% without any clear news.</li>



<li>Alteryx (NYSE:<a href="https://investorplace.com/stock-quotes/ayx-stock-quote/">AYX</a>) stock is jumping over 18% after announcing <a href="https://finance.yahoo.com/news/alteryx-inc-ayx-reports-8-214510186.html">strong earnings results for Q3</a>.</li>



<li>GSE Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/gvp-stock-quote/">GVP</a>) shares are heading nearly 16% higher after <a href="https://www.nasdaq.com/press-release/gse-solutions-awarded-%244.2-million-contract-from-large-utility-for-nuclear-power">announcing a major contract yesterday</a>.</li>



<li>Comera Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmra-stock-quote/">CMRA</a>) stock is getting a more than 15% boost despite a lack of news today.</li>



<li>Lytus Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/lyt-stock-quote/">LYT</a>) shares are up over 14% on Tuesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Ventyx Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtyx-stock-quote/">VTYX</a>) stock is crashing more than 73% alongside <a href="https://finance.yahoo.com/news/ventyx-biosciences-announces-results-phase-210100036.html">lackluster clinical trial results</a>.</li>



<li>Alto Ingredients (NASDAQ:<a href="https://investorplace.com/stock-quotes/alto-stock-quote/">ALTO</a>) shares are plummeting over 54% after releasing its <a href="https://finance.yahoo.com/news/alto-ingredients-inc-alto-reports-213702552.html">Q3 earnings report</a>.</li>



<li>MSP Recovery (NASDAQ:<a href="https://investorplace.com/stock-quotes/lifw-stock-quote/">LIFW</a>) stock is diving more than 26% after a massive rally yesterday. </li>



<li>Ameresco (NYSE:<a href="https://investorplace.com/stock-quotes/amrc-stock-quote/">AMRC</a>) shares are taking an over 22% beating after <a href="https://seekingalpha.com/news/4031339-ameresco-non-gaap-eps-of-0_40-misses-0_06-revenue-of-335_15m-misses-50_02m">missing earnings estimates</a>.</li>



<li>Applied UV (NASDAQ:<a href="https://investorplace.com/stock-quotes/auvi-stock-quote/">AUVI</a>) stock is tumbling more than 21% without any apparent news. </li>



<li>GT Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/gtbp-stock-quote/">GTBP</a>) shares are falling over 20% after announcing details for its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317846172&amp;type=PDF&amp;symbol=GTBP&amp;cdn=855b7ee6662c241f78c358f7ca389e96&amp;companyName=GT+Biopharma+Inc.&amp;formType=DEFA14A&amp;formDescription=Additional+proxy+soliciting+materials+-+definitive&amp;dateFiled=2023-11-06">upcoming shareholder meeting</a>.</li>



<li>Coherus BioSciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/chrs-stock-quote/">CHRS</a>) stock is dropping almost 19% with the release of its <a href="https://www.globenewswire.com/news-release/2023/11/06/2774522/0/en/Coherus-BioSciences-Reports-Third-Quarter-2023-Financial-Results-and-Business-Highlights.html">latest earnings report</a>.</li>



<li>Aura Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/aura-stock-quote/">AURA</a>) shares are decreasing more than 17% after <a href="https://seekingalpha.com/news/4031548-aura-biosciences-announces-pricing-of-public-offering-of-common-stock?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">pricing a public stock offering</a>.</li>



<li>Rush Street Interactive (NYSE:<a href="https://investorplace.com/stock-quotes/rsi-stock-quote/">RSI</a>) stock is dipping over 16% without any news to report today.</li>



<li>Worldwide Webb Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/wwac-stock-quote/">WWAC</a>) shares close out our pre-market stock movers down more than 15% following <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317844325&amp;type=PDF&amp;symbol=WWACW&amp;cdn=47217a2550669412a8ad4652d43a604e&amp;companyName=Worldwide+Webb+Acquisition+Corp.+Warrant&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-11-06">an update on its merger</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766529">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
		<div>
			<div></div>
						<div></div>
					</div>
	</div>The post <a href="https://investorplace.com/2023/11/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-nov-7th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday